Morepen Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹35.71
- Today's High:
- ₹39.14
- Open Price:
- ₹39.14
- 52W Low:
- ₹23.65
- 52W High:
- ₹48.4
- Prev. Close:
- ₹38.84
- Volume:
- 497421
Company Statistics
- Market Cap.:
- ₹20.39 billion
- Book Value:
- 14.619
- Revenue TTM:
- ₹15.24 billion
- Operating Margin TTM:
- 4.58%
- Gross Profit TTM:
- ₹4.44 billion
- Profit Margin:
- 3.13%
- Return on Assets TTM:
- 3.31%
- Return on Equity TTM:
- 5.81%
Company Profile
Morepen Laboratories Limited had its IPO on under the ticker symbol MOREPENLAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Morepen Laboratories Limited has a staff strength of 0 employees.
Stock update
Shares of Morepen Laboratories Limited opened at ₹39.14 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹35.71 - ₹39.14, and closed at ₹35.98.
This is a -7.36% slip from the previous day's closing price.
A total volume of 497,421 shares were traded at the close of the day’s session.
In the last one week, shares of Morepen Laboratories Limited have slipped by -7.93%.
Morepen Laboratories Limited's Key Ratios
Morepen Laboratories Limited has a market cap of ₹20.39 billion, indicating a price to book ratio of 2.1194 and a price to sales ratio of 1.064.
In the last 12-months Morepen Laboratories Limited’s revenue was ₹15.24 billion with a gross profit of ₹4.44 billion and an EBITDA of ₹1.01 billion. The EBITDA ratio measures Morepen Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Morepen Laboratories Limited’s operating margin was 4.58% while its return on assets stood at 3.31% with a return of equity of 5.81%.
In Q2, Morepen Laboratories Limited’s quarterly earnings growth was a positive 163.6% while revenue growth was a positive 33%.
Morepen Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 41.9895
- PEG
Its diluted EPS in the last 12-months stands at ₹0.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Morepen Laboratories Limited’s profitability.
Morepen Laboratories Limited stock is trading at a EV to sales ratio of 1.0497 and a EV to EBITDA ratio of 13.2404. Its price to sales ratio in the trailing 12-months stood at 1.064.
Morepen Laboratories Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹11.10 billion
- Total Liabilities
- ₹3.21 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Morepen Laboratories Limited ended 2024 with ₹11.10 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹11.10 billion while shareholder equity stood at ₹7.53 billion.
Morepen Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.21 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹744.74 million in goodwill. Its cash balance stood at ₹216.66 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹9.34 million.
Morepen Laboratories Limited’s total current assets stands at ₹7.56 billion while long-term investments were ₹0 and short-term investments were ₹401.52 million. Its net receivables were ₹2.63 billion compared to accounts payable of ₹2.27 billion and inventory worth ₹2.29 billion.
In 2024, Morepen Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Morepen Laboratories Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹35.98
- 52-Week High
- ₹48.4
- 52-Week Low
- ₹23.65
- Analyst Target Price
- ₹
Morepen Laboratories Limited stock is currently trading at ₹35.98 per share. It touched a 52-week high of ₹48.4 and a 52-week low of ₹48.4. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹34 and 200-day moving average was ₹30.1 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4829.2% of the company’s stock are held by insiders while 85.6% are held by institutions.
Frequently Asked Questions About Morepen Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Morepen Laboratories Limited operates as a pharmaceutical and healthcare products company in India. The company manufactures active pharmaceutical ingredients (APIs), home diagnostics, formulations, and over the counter products. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic drugs, anti- coagulant, anti-gout, and anti- malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, blood glucose test strips, and heat belt. It also provides Burnol, first degree/minor burns cream; Fiber-X, a sat isabgol; fever X for fever; Pain X for pain; Acidity X for acidity; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti- allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers its over-the-counter products under the Dr. Morepen brand. It also exports its products. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.